At present, bevacizumab, a humanised monoclonal antibody that targets VEGF-A, is undergoing clinical evaluation (in association with EGFR-targeted drugs) in HNSCC (Caponigro et al, 2005). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.